The Commission on Human Medicines and its Pharmacovigilance Expert Advisory Group considered a review of the risks and benefits of Nicobrevin—a multi-ingredient antismoking preparation containing quinine, menthyl valerate, camphor, and eucalyptus oil. The Commission noted the lack of evidence for efficacy of Nicobrevin as an aid to smoking cessation and the association of quinine and camphor with adverse reactions. Furthermore, none of the antismoking organisations recommend Nicobrevin as an aid to cessation.  The risks of the product are considered to outweigh any benefits.  Clinic Europe offer a proven antismoking product, Champix - from Pfizer.